AxoGen Outlines 18%+ Growth Target for 2026

Biologics License Approval, Debt Paydown Fuel Optimistic Outlook

Mar. 11, 2026 at 9:44am

Got story updates? Submit your updates here. ›

AxoGen (NASDAQ:AXGN) executives detailed a year of accelerating commercial momentum, recent balance sheet improvements, and the operational implications of its December Biologics License Application (BLA) approval for AVANCE during a recent investor discussion. The company expects at least 18% top-line growth in 2026, driven by early-stage market penetration across multiple areas including trauma, oral maxillofacial, breast, and head and neck procedures.

Why it matters

AxoGen's BLA approval for its AVANCE nerve graft product is a significant milestone, allowing the company to reengage with payers and unlock new operational efficiencies. The company's optimistic 2026 growth outlook reflects confidence in its ability to capitalize on unmet demand for its nerve repair solutions across various surgical specialties.

The details

AxoGen raised $142 million in a recent capital raise, using $68 million to eliminate debt and improve its balance sheet. The company expects a $17 million loss in Q1 2026 but anticipates stronger cash generation going forward. Management attributed the 18%+ growth target to factors like account targeting, expanding surgeon capability, and disciplined sales management. The BLA approval also allows AxoGen to reengage with payers who had previously classified its products as experimental.

  • AxoGen received BLA approval for AVANCE in December 2025.
  • The company expects to begin selling biologic-labeled AVANCE in Q2 2026.
  • AxoGen expects to implement manufacturing and process improvements in 2027 to improve gross margins.

The players

AxoGen, Inc.

A Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage.

Mike

The Chief Executive Officer of AxoGen.

Lindsey

The Chief Financial Officer of AxoGen.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

AxoGen's BLA approval and balance sheet improvements position the company to capitalize on unmet demand for its nerve repair solutions, with a focus on driving growth across multiple surgical specialties and improving operational efficiency to boost profitability.